Delivery Order SPE2DB22D2211-SPE2DB25FSBSZ
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,760.43, is for the delivery of 4563398480 NOVOSeven RT 2 MG vials and has a completion date of February 12, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
- This federal contract award is for the delivery of NovoSeven RT 5 mg vials to the Defense Logistics Agency (DLA). The $80,051.84 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on March 14, 2025, with a completion date of April 4, 2025. This award is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a...
- The Defense Logistics Agency has awarded a delivery order valued at $5,772.72 to AmerisourceBergen Drug Corp for the supply of Novoseven RT 2 mg vials. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply agreement extending through December 2026. The delivery order is scheduled for completion by August 15, 2025, with fulfillment...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $35,750.80 firm fixed-price delivery order is for the supply of 4,566,658,071 units of the medication NovoSeven RT 5 mg vials. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of...
- This federal contract award, valued at $6,911.29, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of NovoSeven RT 5 mg vials, a pharmaceutical product. This award is a delivery order under a single-award Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $42,900.96 Firm Fixed Price delivery order contract is for the supply of NovoSeven RT 5 mg vials, a specialty medication. The contract has an ultimate completion date of December 23, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,932.23, is for the supply of a variety of pharmaceutical products and medical supplies, including medications across multiple therapeutic domains such as diabetes, neurology, pain management, and antibiotics. This delivery order is part of a larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,404.40 by the Defense Logistics Agency's Medical Supply Chain on July 21, 2025. The contract is structured as a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-competitive award under an existing indefinite delivery contract vehicle. This delivery order is a child contract under...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The $7,958.64 firm fixed price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that runs through November 2026. The IDC enables the DLA to procure a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,404.56 contract has an ultimate completion date of March 11, 2025 and is not designated with a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSBSZDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,512.66 to AmerisourceBergen Drug Corp for 1,500 unit vials of Novoeight, a pharmaceutical product, with performance in Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, and represents a child contract under a larger indefinite delivery vehicle. No set-aside designation was applied to this procurement. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and defense programs globally. The firm's federal contract portfolio demonstrates extensive experience fulfilling specialized medical procurement requirements across multiple therapeutic domains through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 7/28/25 |